From hydration to hygiene: Why Prestige Consumer Healthcare is doubling down on dry eye innovation

Prestige Consumer Healthcare Inc. (NYSE: PBH) has announced two new additions to its TheraTears dry eye portfolio—Eyelid Cleansing Wipes and Dry & Tired Preservative Free Lubricant Eye Drops—slated for nationwide rollout in February 2026. The launch underscores the company’s growing emphasis on digital eye strain as a high-frequency, under-addressed segment in the broader over-the-counter (OTC) ophthalmic care market.

Both products will be made available across major retail channels including Amazon, Walmart, and Walgreens, targeting digitally active consumers with persistent dryness and fatigue linked to extended screen use. The introduction positions Prestige Consumer Healthcare to capture incremental demand beyond traditional dry eye therapy users, moving into a higher-volume, lifestyle-driven subsegment.

Why is Prestige Consumer Healthcare investing in screen-fatigue specific eye care formats?

TheraTears’ Dry & Tired Lubricant Eye Drops are explicitly formulated for individuals experiencing ocular discomfort from prolonged exposure to digital screens, an issue that has scaled with hybrid work and online entertainment trends. According to internal product claims, the drops feature twice the hydrating ingredient concentration found in the original preservative-free formula and are delivered via single-use vials to cater to users with heightened sensitivity.

In parallel, the Eyelid Cleansing Wipes cater to the daily hygiene aspect of dry eye management. Packaged in a portable, non-stinging format, these wipes aim to reinforce TheraTears’ positioning in daily ocular maintenance—similar to the skin-care industry’s pivot toward preventive care routines.

This bifocal product expansion reflects a broader trend in OTC categories where brands are pushing toward situational specificity—offering differentiated solutions for tired, dry, or screen-fatigued eyes rather than relying on general-purpose relief.

How does this fit into Prestige Consumer Healthcare’s broader brand architecture?

TheraTears, acquired by Prestige Consumer Healthcare in 2017, is one of several vertically integrated brands within the company’s diverse OTC portfolio. While flagship brands such as Monistat and DenTek dominate their respective categories, the eye care vertical—driven by TheraTears and Clear Eyes—has become a strategic growth lever in recent years, especially following post-pandemic consumer demand for at-home health solutions.

The launch of these two products serves as both a category defense and a portfolio enhancement. It allows Prestige Consumer Healthcare to address overlap with its Clear Eyes brand, which is also marketed for redness and lubrication, while drawing a sharper therapeutic distinction based on formulation (e.g., preservative-free, screen-use specificity) and application (e.g., lid cleansing versus traditional drops).

Critically, it allows TheraTears to lean into its origin story—a doctor-created, science-backed brand founded by Harvard-trained ophthalmologist Dr. Jeffrey Gilbard. The incorporation of a proprietary electrolyte blend and longer-lasting hydration claims serve to differentiate its offering in a crowded field where price and brand trust drive consumer decisions.

Could digital eye strain become the next major OTC growth vector?

Prestige Consumer Healthcare’s move signals a broader bet that digital eye strain is not just a passing concern but a structural consumer shift. Between increased screen time among children, video conferencing fatigue in adults, and rising awareness of “tech-driven dryness,” screen fatigue is increasingly being diagnosed as part of the dry eye disease spectrum.

This growing convergence creates a prime opportunity for new product introduction, especially in preservative-free or clean-label segments. While traditional competitors like Bausch + Lomb or Alcon dominate clinical treatment options, Prestige Consumer Healthcare appears intent on fortifying its over-the-counter moat through differentiated daily-use products.

The single-use packaging, preservative-free formulations, and convenient retail availability are designed to appeal to self-managing consumers, especially younger adults and remote workers who prefer flexible, non-prescription solutions.

What could execution risks and retail dynamics look like in 2026?

Despite category alignment, execution risk for Prestige Consumer Healthcare will hinge on three fronts: retail shelf allocation, digital marketing efficacy, and customer education. With limited SKU bandwidth at major pharmacies and grocery chains, the success of the TheraTears wipes and drops may depend on displacing either competitor products or older in-brand variants.

On e-commerce platforms like Amazon, the product’s visibility will be driven by advertising spend and review velocity. Here, competitor crowding is a real concern as the eye care category has seen a surge in new direct-to-consumer brands pushing preservative-free or herbal alternatives.

Another potential friction point is user education. While consumers are broadly familiar with eye drops, eyelid wipes are still an emerging category. Without strong in-store guidance or targeted digital content, conversion may be slower among new buyers unless bundled with existing dry eye therapies or promoted through clinician networks.

Still, Prestige Consumer Healthcare’s operational leverage across manufacturing, distribution, and category management offers a credible base for pushing these new SKUs through initial retail inertia.

What does this suggest about Prestige Consumer Healthcare’s capital allocation strategy?

The February 2026 TheraTears launch arrives during a broader rebalancing of Prestige Consumer Healthcare’s portfolio. As growth slows in mature OTC categories, the company appears to be investing selectively in extensions that combine adjacent category opportunity with high-frequency use cases.

This is consistent with Prestige Consumer Healthcare’s M&A and product strategy—targeting niche but scalable segments that lend themselves to brand trust, routine usage, and low clinical complexity. By anchoring expansion within an existing doctor-backed brand like TheraTears, the company avoids the cost and risk of establishing entirely new brand equity while unlocking new usage occasions that feed directly into its recurring revenue base.

With OTC market fragmentation increasing and wellness becoming a mainstream consumer focus, precision in positioning and regulatory clarity around claims will likely define future product success. Prestige Consumer Healthcare’s conservative but focused expansion in this space reflects a capital-light strategy that prioritizes brand extensions over risky pipeline bets.

What does Prestige Consumer Healthcare’s TheraTears expansion signal for OTC eye care strategy in 2026?

• Prestige Consumer Healthcare is expanding TheraTears into two new SKUs targeting screen-induced eye strain and daily lid hygiene, reflecting deeper segmentation in the dry eye market.

• The February 2026 launch supports the company’s strategy of pushing high-frequency, consumer-led OTC formats that do not require physician intervention.

• The preservative-free eye drops and eyelid wipes are positioned to compete with emerging clean-label DTC brands as well as clinical incumbents like Bausch + Lomb and Alcon.

• Retail execution will be critical as shelf space, consumer education, and e-commerce visibility determine near-term adoption.

• The launch aligns with growing consumer awareness of digital eye fatigue, signaling an intent to build category leadership around screen-related dryness.

• Prestige Consumer Healthcare is continuing to invest in extensions of its most trusted doctor-founded brands rather than launching untested new lines.

• The company’s broader capital allocation strategy appears to favor incremental revenue growth from routine OTC wellness products that align with its established distribution network.

• If successful, TheraTears’ expansion could trigger similar segmentation trends across OTC categories, redefining how brands respond to lifestyle-specific health concerns.